Lilly’s Retevmo Gets FDA OK for RET Fusion-Positive Solid Tumors

Lilly’s Retevmo was granted accelerated approval by the US FDA for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

• Continued approval may be contingent upon verification of clinical benefit in confirmatory trials

To view the source of this information, click here

To contact the reporter on this story:
Greg Chang in San Francisco at gchang1@bloomberg.net

To contact the editor responsible for this story:
Chakradhar Adusumilli at cadusumilli@bloomberg.net

© 2022 Bloomberg L.P. All rights reserved. Used ...